Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorÖzel, Merve
dc.contributor.authorBaşkol, Gülden
dc.contributor.authorBaşkol, Mevlüt
dc.contributor.authorGüneş, Fatma
dc.contributor.authorUçar, Çiğdem
dc.contributor.authorDoğru, Büşra Nur
dc.contributor.authorAkalın, Hilal
dc.date.accessioned2023-09-06T08:43:14Z
dc.date.available2023-09-06T08:43:14Z
dc.date.issued2022en_US
dc.identifier.citationÖzel, M., Başkol, G., Başkol, M., Güneş, F., Uçar, Ç., Doğru, B. N., & Akalın, H. (2022). SAHA induce hippo pathway in CCA cells without increasing cell proliferation. Molecular Biology Reports, 49(5), 3649-3656.en_US
dc.identifier.issn03014851
dc.identifier.urihttps://doi.org/10.1007/s11033-022-07204-8
dc.identifier.urihttps://hdl.handle.net/20.500.12513/5299
dc.description.abstractBackground: Cholangiocarcinoma is a malignant tumor originating from bile duct epithelial cells. Since tumor metastasis is associated with poor prognosis and short-term survival of patients, there is an urgent need for alternative therapeutic approaches for CCA. Because of that reason, we aimed to investigate effect of SAHA which is known as HDAC inhibitor on extrahepatic cholangiocarcinoma cell line (TFK-1). Methods: Cell cycle was measured by Muse Cell Analyzer. YAP, TAZ, TGF-β protein levels were determined by western-blotting method. TEAD (1–3), TIMP2 and TIMP3 genes level were determined by real-time PCR analysis. Results: We have seen the positive effects of SAHA on the TFK-1 cell line as it reduces cell viability and arresting cells in the G0/G1 phase. We also observed the negative effects of SAHA, as it increases the expression levels of YAP, TAZ, TGF-β protein and TEAD (1–3) gene. We also found that SAHA reduced the expression levels of TIMP2 and TIMP3 in TFK-1 cells, but was not statistically significant. Conclusions: Although observing its antiproliferative effects, these negative effects may be related to the cells being resistant to the drug or the remaining cells having a more aggressive phenotype. Therefore, we think that caution should be exercised in the use of this drug for CCA treatment. © 2022, The Author(s), under exclusive licence to Springer Nature B.V.en_US
dc.language.isoengen_US
dc.publisherSpringer Science and Business Media B.V.en_US
dc.relation.isversionof10.1007/s11033-022-07204-8en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCholangiocarcinomaen_US
dc.subjectHippo pathwayen_US
dc.subjectSuberoylanilide hydroxamic aciden_US
dc.subjectYAP/TAZen_US
dc.titleSAHA induce hippo pathway in CCA cells without increasing cell proliferationen_US
dc.typearticleen_US
dc.relation.journalMolecular Biology Reportsen_US
dc.contributor.departmentTıp Fakültesien_US
dc.contributor.authorIDHilal Akalın / 0000-0002-2580-836Xen_US
dc.identifier.volume49en_US
dc.identifier.issue5en_US
dc.identifier.startpage3649en_US
dc.identifier.endpage3656en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster